Fever is the most common manifestation of the innate immune response to invading pathogens. Animals prevented from developing fever have increased morbidity and mortality to infection. We now show that early life events can program this innate immune response, in that rats that have been challenged neonatally with the immune stimulant lipopolysaccharide (LPS) have both suppressed febrile responses to LPS as adults and significantly reduced nuclear factor (NF)-κB activation in peripheral immune organs. This was associated with reduced levels of proinflammatory cytokines tumor necrosis factor (TNF)-α, and interleukin-6 (IL-6) in the plasma after adult LPS challenge, compared with animals that have received saline neonatally. In contrast, adult LPS challenge elicited higher corticosterone levels in the animals that had been treated neonatally with LPS. When this increased corticosterone response was negated by adrenalectomy or by administration of the glucocorticoid receptor antagonist RU-486, both the cytokine and febrile responses were normalized. This study indicates that the innate immune response can be programmed by a neonatal LPS challenge, whereby an amplified hypothalamicpituitary-adrenal response causes reduced cytokine synthesis and an attenuated febrile response to an adult immune challenge. In light of the importance of fever in the host defense response, these alterations may have deleterious consequences on an individual's ability to combat disease later in life.
One of the major targets of these signaling mediators is the central nervous system (CNS), which responds by initiating a series of autonomic and neuroendocrine responses, the most common manifestation of which is fever. This phylogenetically ancient response to infection is thought to have "survival value" through its ability to induce cytokine expression and reduce bacterial loads (3) . Animals prevented from developing fever during infection have greater morbidity and mortality than animals allowed to develop fever (3, 4) . Any alteration in an individual's ability to mount appropriate febrile responses could then have serious consequences on his or her ability to effectively combat disease throughout life.
The most well-studied activator of the innate immune response is lipopolysaccharide (LPS), derived from the outer coat of gram-negative bacteria. Upon binding to its receptor, LPS initiates a series of phosphorylation events, ending with the phosphorylation of the inhibitory κB (IκB) molecule. When this molecule is phosphorylated, it releases the transcription factor nuclear factor (NF)-κB, allowing it to translocate into the nucleus. In the nucleus, NF-κB promotes transcription of various proinflammatory cytokines, such as tumor necrosis factor (TNF)-α, interleukin-1β (IL-1β), and IL-6 (5-7). These cytokines target the CNS to induce cyclooxygenase-2 (COX-2) to synthesize prostaglandin E 2 (PGE 2 ), which then acts within the ventral median preoptic area and the anterior hypothalamus to activate heat production and conservation mechanisms to generate fever (for review see ref 8) . The actions produced by these proinflammatory cytokines are held in balance by activation of coincident anti-inflammatory pathways, such as the synthesis of IL-1 receptor antagonist and IL-10 (9, 10), or by activation of neuroendocrine pathways such as the hypothalamic-pituitary-adrenal (HPA) axis (11, 12) . The end product of this latter pathway, corticosterone, has potent anti-inflammatory properties due to its ability to inhibit the production of the proinflammatory mediators.
We have recently shown that postnatal day 14 (P14) rats given a single LPS challenge display attenuated febrile and CNS neurochemical responses to an adult LPS challenge, compared with animals that had received saline neonatally (1) . In contrast, the febrile responses to central injections of PGE 2 or to peripheral injection of IL-1β were not changed by this early life immune challenge. These results led us to hypothesize that there is an alteration in the profile of cytokine and hormonal responses to an adult LPS challenge and that this alteration is the underlying mechanism behind this novel programming of the innate immune response by a single neonatal LPS challenge.
MATERIALS AND METHODS

Animals
Pregnant female Sprague-Dawley rats (Charles River) were maintained at 22°C on 12 h light/dark cycle (7 AM-7 PM), where food and water were available ad libitum. Seven days after birth (P7) all litters were culled to 12 pups. On P14, six pups per litter were randomly selected, and LPS (100 μg/kg ip; Sigma, E. Coli, serotype 026:B6) was administered in sterile saline (1 μl/mg body wt). Six control pups were administered an equivalent volume of sterile, pyrogenfree saline. Litters were weaned at 21 days, and male rats were housed four to six animals per cage until they reached 2-3 months of age. After this, animals were housed two per cage for the remainder of the experiments. All procedures were in accordance with the Canadian Council on Animal Care regulations and were approved by the local University of Calgary animal care committee.
Body temperature recording
Adult male rats were anesthetized with halothane (induced at 4%, maintained at 2%), and silicone-coated temperature data loggers (SubCue, Calgary, Canada) were surgically implanted into the abdomen. After a 5-day recovery, adult rats received 50 μg/kg LPS dissolved in sterile saline, and body temperature measurements were taken every 15 min for 8 h. This dose of LPS has been used previously in our laboratory (13) to elicit fevers in adult rats. Control animals received an equivalent volume of sterile, pyrogen-free saline.
Immunoblot
Male rats that had been treated neonatally with saline or LPS were given LPS (50 μg/kg ip) or saline as adults. Two hours later all animals were deeply anesthetized with sodium pentobarbital (80-100 mg/kg ip) and perfused with phosphate-buffered saline at 4°C via the left cardiac ventricle to clear the tissue of blood. Liver and spleen tissue were removed and snap frozen in liquid nitrogen. Proteins were then extracted, and 90 μg aliquots were separated by 10% SDS PAGE as described previously (1, 13) . Proteins were then transferred to a nitrocellulose membrane and incubated overnight at 4°C in a 1:500 dilution of affinity purified rabbit antiphosphorylated-IκB-α antibody (Santa Cruz Biotechnology, catalog no. sc-7977) diluted in 5% fat-free milk in Tris-buffered saline containing Tween-20. Membranes were then washed and incubated for 1 h in 1:4000 goat anti-rabbit IgG horseradish-peroxidase conjugate (Santa Cruz Biotechnology, sc-2004) at room temperature. Bound antibodies were revealed using enhanced chemiluminescence assay (ECL; Pierce, Rockford, IL). After the bands were detected, the membrane was stripped with 2-mercaptoethanol (BDH) and reblotted with rabbit anti-actin antibody (Sigma, catalog no. A2066) at a 1:10,000 dilution.
Cytokine measurement
Male rats treated neonatally with saline or LPS were administered LPS (50 μg/kg ip) or saline as adults. Plasma samples were taken 2 h after LPS administration. At this time, the plasma levels of the proinflammatory cytokines TNF-α, IL-1β, and IL-6 were all reported to be significantly increased, and at or near maximal, after LPS challenge (14) (15) (16) (17) . All animals were deeply anesthetized, and aliquots of blood were then taken via left ventricular cardiac puncture, collected in heparinized tubes and immediately centrifuged at 4°C (10,000 rpm for 10 min). The plasma was collected in multiple aliquots, snap frozen in liquid nitrogen, and stored at -70°C. Cytokine analysis for IL-1β, TNF-α, and IL-6 was performed using a rat cytokine/chemokine LINCOplex kit (Linco diagnostic services, St. Charles, MO, catalog no. RCYTO-80K) or standard ELISA kits (Bioscience, Camarillo, CA). The precision of the LINCOplex kit was as follows: inter-assay variability = 8.1-14.2% CV; intra-assay variability = 3.7-9.1% CV. The sensitivity of this assay is 25 pg/ml. The precision of the Biosource ELISA kits was as follows: inter-assay variability = 4.3-10% CV; intra-assay variability = 2.7-8.2% CV. The sensitivity was 3-8 pg/ml.
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Corticosterone ELISA All animals in this experiment were handled twice daily (10 AM/3 PM) for a period of 2 min on 7 consecutive days before experimentation to minimize any stress-induced changes in corticosterone secretion in the time between handling and plasma sample collection (~1 min). On day 7, animals from both neonatal treatment groups were injected with LPS (50 μg/kg ip) during the morning handling period. Trunk blood samples were obtained thereafter at various time points by decapitation, with blood samples collected in heparinized tubes. Samples were immediately spun at 4°C (10,000 rpm for 10 min) and snap frozen in liquid nitrogen. All samples were stored at −70°C. A corticosterone ELISA kit (DE3600, R&D Systems, Minneapolis, MN) was used to assay the plasma samples for free corticosterone. The precision of this assay was as follows: interassay variability = 7.8−13.1% CV; intra-assay variability = 6.7−8.0% CV. The sensitivity of this assay is 27 pg/ml.
Adrenalectomy
Adult male rats treated neonatally with either LPS or saline were adrenalectomized (ADX) under aseptic conditions, and temperature data loggers (SubCue) were implanted into the abdominal cavity along with Alzet mini-osmotic pumps (Alza Pharmaceuticals, Palo Alto, CA). These miniosmotic pumps contained 240 μl corticosterone (10 mg/ml, Sigma) suspended in polyethylene glycol, delivered at 10 μg/h, a dose used previously to obtain physiological levels of corticosterone in the circulation (18) . Animals were treated postoperatively with Derapen (Ayerst Labs, Montreal, QC, Canada) and given a bolus of corticosterone (2 mg) injected subcutaneously into the nape of the neck. All animals were then returned to their home cages and maintained on a diet of standard rat chow and 0.9% NaCl. The survival rate of this procedure was 100%, with animals having normal body temperature within 24 h after the surgery. After a 1 wk recovery period, all ADX animals were challenged with LPS (50 μg/kg ip) and body temperature measurements were taken every 15 min for a period of 8 h.
RU-486
Adult animals from both neonatal treatment groups had temperature data loggers implanted into the abdominal cavity to measure core body temperature and were allowed 1 wk for recovery. On the day of the experiment, animals were injected with 50 mg/kg RU-486 (Mifepristone, Sigma) dissolved in DMSO or DMSO alone as a control. This dose of RU-486 has been shown to block both the peripheral and central effects of circulating corticosterone (19, 20) . Thirty minutes after injection of the RU-486 or vehicle, all animals received LPS (50 μg/kg ip) and temperature was recorded every 15 min for a period of 8 h. In a separate group of animals, blood samples were taken 2 h after LPS challenge and assayed for proinflammatory cytokines as described previously.
Data analysis
Fever data were calculated as a fever index (°C × h) between 60 and 360 min after LPS challenge (a time after the stress-induced hyperthermia had subsided) and subjected to a Student's t test. Average baseline temperatures (time: 60 to 0 min) were compared statistically before any analysis was performed. Protein levels were quantified by densitometry analysis to give P-
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IκB/actin ratios, thus providing a semiquantitative value, and were compared using a two way ANOVA with Student Newman Keuls post-hoc comparison. Cytokine data were compared using a Student's t test or two-way ANOVA with Student Newman Keuls post-hoc comparison. Corticosterone responses were compared using a two-way ANOVA, with a Student Newman Keuls post hoc test. All data are means ± SE. Significance was accepted at P < 0.05.
RESULTS
Animals treated neonatally with LPS show an attenuated adult febrile response to LPS and reduced plasma levels of proinflammatory cytokines
We measured the adult febrile responses to LPS in animals that had been challenged neonatally with either LPS or saline. The neonatal LPS treatment did not affect either the baseline body temperature or the stress-induced hyperthermia elicited by the handling of the animals, when compared with the saline controls ( Fig. 1A; Fig. 1B -D, neither LPS nor saline administration during the neonatal period altered the basal levels of circulating proinflammatory cytokines in the plasma after an adult saline injection (n=4, P>0.05). When stimulated with LPS, animals that received saline as neonates displayed the typical rise in the proinflammatory cytokines TNF-α, IL-1β, and IL-6 (21, 22) . In contrast, animals that had received LPS as neonates displayed significant reductions in TNF-α and IL-6 levels when challenged with LPS as adults compared with those animals treated neonatally with saline and challenged as adults with LPS ( Fig. 1B and D; n=9, P<0.05 ). This reduction in proinflammatory cytokines highly correlates with the reduced febrile temperatures seen 2 h after adult LPS challenge. A similar, but nonsignificant, trend was also seen with IL-1β ( Fig. 1C; n=9, P>0 .05).
Animals treated neonatally with LPS have a reduction in the amount of phosphorylated IκB-α after adult LPS challenge
It has been previously shown that the liver and spleen both play important roles as sources for circulating cytokines. The liver sequesters ~50% of the circulating LPS, with the spleen having the next highest concentration (23, 24) . Additionally, these immune organs can produce large quantities of cytokines in response to LPS (16, 17, 25, 26) ; hence immune activation of these organs largely contributes to the circulating pool of cytokines. To determine the amount of activated NF-κB in the spleen and liver, we used semiquantitative Western blot analysis to measure the amount of P-IκB-α (values expressed relative to the amount of the actin). All data were normalized to the ratio of P-IκB-α/actin in the group of animals that had received saline both as neonates and as adults (S/S, expressed as 100%). The basal levels (adults treated with saline) of P-IκB-α were not significantly different (P>0.05) in either the spleen (Fig. 2A) or the liver (Fig. 2B ) in adult animals from either neonatal treatment group. When challenged with LPS as adults, the amount of P-IκB-α in animals that had received saline as neonates was significantly increased (n=9, P<0.05) in both the spleen and the liver. However, there was not a significant LPS-induced increase in the amount of P-IκB-α (n=9, P>0.05) in either the spleen or the liver in adult animals that had been treated neonatally with LPS. This indicates that a neonatal LPS challenge can result in a reduced amount of phosphorylated IκB-α, thus reflecting reduced activation of NF-κB, in response to an adult LPS challenge.
Animals treated neonatally with LPS show increased corticosterone responses to LPS as adults
Because of the potential ability of corticosteroids to modify cytokine expression, we asked if the reduction in circulating cytokines is associated with a sensitized HPA response to the adult LPS challenge. Trunk blood samples from both neonatal treatment groups were assayed for free corticosterone in the plasma at various times after adult LPS challenge. The basal levels of free corticosterone were unchanged between the neonatal LPS and saline groups ( Fig. 3; t=0 min,  n=5, P>0.05) . After adult LPS challenge, both groups showed a significant increase in corticosterone after LPS ( Fig. 3; n=6, P<0.05) ; however, the peak corticosterone response in animals that had been exposed neonatally to LPS was significantly higher than the peak response in animals treated neonatally with saline ( Fig. 3; t=60 min, n=6, P<0 .05). By 120 min after the adult LPS challenge, the corticosterone levels were not different between the two groups but were still significantly higher than baseline values.
Blocking the corticosterone effect by either adrenalectomy or RU-486 restored both the febrile and cytokine responses to an adult LPS challenge
To assess whether the increase in the plasma corticosterone was contributing to the attenuated febrile response, animals from both neonatal treatment groups were adrenalectomized as adults. In response to an adult LPS challenge, adrenalectomized animals treated neonatally with LPS or saline displayed almost identical febrile responses ( Fig. 4A ; fever index: 3.55±0.64 vs. 3.38±0.72°C × h, n=5, P>0.05). To confirm that this normalization of the febrile response was due to the loss of corticosterone and not due to other alterations caused by the adrenalectomy, an additional group of animals was treated with RU-486 before adult LPS challenge. In these experiments, RU-486 or vehicle was given 30 min before the adult LPS challenge. The vehicle alone (DMSO) did not have any effect on normal body temperature. When animals were given RU-486 before adult LPS challenge, both neonatal treatment groups had almost identical febrile responses ( Fig. 4C ; fever index: 3.5±0.48 vs. 3.40±0.84°C × h, n=7, P>0.05). In contrast, a separate group of animals was given vehicle alone before adult LPS challenge and again the febrile response of animals treated neonatally with LPS were attenuated compared with animals treated neonatally with saline ( Fig. 4B; fever To determine if the RU-486 effects were due to the known action of corticosterone to suppress cytokine synthesis, we measured the plasma levels of proinflammatory cytokines after adult LPS challenge. In this study, RU-486 was injected 30 min before the adult LPS challenge. Plasma samples were taken 2 h after the adult LPS challenge (adult cytokine response to LPS is significantly attenuated at this time in LPS-treated neonates). The treatment with RU-486 reversed the previously observed reduction in cytokine levels seen in LPS pretreated animals; that is, animals treated neonatally with either LPS or saline produced similar levels of the proinflammatory cytokines TNF-α, IL-1β, and IL-6 after LPS when the effects of corticosterone were blocked ( Fig. 4D-F; n=7, P>0 .05).
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DISCUSSION
We have shown in this study that a single exposure to LPS during the neonatal period results in a long-lasting alteration in the innate immune response to infection as adults. This is manifested as a reduced febrile response, due to an attenuated production of proinflammatory cytokines after an adult LPS challenge. The mechanism underlying this reduction in inflammatory cytokines is associated with an exaggerated HPA (corticosterone) response to the adult LPS challenge. The increased plasma corticosterone concentration (60 min) is temporally well situated to inhibit the production of proinflammatory cytokines (120 min) responsible for the generation of the febrile response. This is supported by our observation that by blocking the effects of this increased corticosterone response, we could abolish the attenuated febrile and cytokine responses to an adult immune challenge. These results give causal evidence that the heightened HPA activity is responsible for the suppressed febrile response seen in animals treated neonatally with LPS. This suggests a novel form of immunological plasticity caused by a neonatal immune stimulus, wherein a single LPS challenge can alter the innate immune response well into adulthood.
The actions of circulating proinflammatory cytokines underlie the febrile response to intraperitoneal LPS challenge (27) (28) (29) . Mice that lack the ability to produce these proinflammatory cytokines display highly attenuated inflammatory responses (30) . Previously, we had shown that the adult febrile responses to an exogenously applied cytokine were unaltered by neonatal LPS challenge (1) leading us to hypothesize that the reduced fever may be due to an attenuated production of proinflammatory cytokines after adult LPS challenge. Our data support this hypothesis, showing that animals treated neonatally with LPS have a significantly reduced plasma level of proinflammatory cytokines TNF-α and IL-6 after an adult LPS challenge.
So, what is the mechanism underlying the highly attenuated levels of these cytokines? Previous studies have shown that activation of the HPA axis, resulting in the release of corticosterone, can play an important role in limiting the febrile response generated after an LPS challenge (31, 32) . Our results show an increase in the sensitivity of the HPA axis in animals that had been challenged neonatally with LPS, resulting in an increased level of free corticosterone after adult LPS challenge. A previous study by Shanks et al. (33) has shown a similar phenomenon with repeated neonatal immune challenges. In addition, for the first time we are able to implicate this elevated corticosterone response in the suppression of the febrile response, in that either adrenalectomy to eliminate circulating corticosterone, or blockade of glucocorticoid receptors with RU-486 reverses both the attenuated cytokine response and the suppressed fever seen in animals that have been treated neonatally with LPS.
There are several mechanisms by which corticosteroids can act as endogenous antipyretics: 1) through the induction of IκB-α protein synthesis, resulting in more bound NF-κB (19, 34, 35) , 2) direct protein-protein interaction with NF-κB (36-38); and 3) via direct competition for DNA binding domains with NF-κB (39) . The end result of the action of LPS-induced corticosterone is the inhibition of NF-κB activated cytokine gene transcription after an immune challenge (40). We do not know which of these actions of corticosterone is responsible for the attenuated inflammatory response; however, our data show that animals treated neonatally with LPS exhibit reduced P-IκB in peripheral tissues in response to LPS, indicating that there is a reduced amount of NF-κB activation. In addition to acting on NF-κB, glucocorticoids can also directly inhibit the expression of cyclooxygenase (COX)-2 (41, 42), a rate-limiting enzyme in the production of pyrogenic prostaglandins. In our previous study, it was shown that the levels of LPS-induced COX-2 in the hypothalamus were significantly reduced in animals treated neonatally with LPS (1). This reduction in COX-2 may be due not only to decreased proinflammatory cytokine levels but also to a direct inhibition of its production by glucocorticoids. In either case, it is likely that an altered glucocorticoid response can exhibit potent antipyretic effects by inhibiting various aspects of the neuro-immune response.
Although our data unambiguously show that the result of a neonatal LPS challenge is an amplified corticosterone response, which has the ability to reduce cytokines and attenuate the generation of fever, they do not reveal the mechanism underlying the exaggerated corticosterone response. It is unlikely that the attenuated levels of proinflammatory cytokines are responsible for the enhanced HPA response, as all available evidence indicates that TNF-α, IL-1β, and IL-6 increase corticosterone secretion (43) (44) (45) (46) , indicating that another mechanism is responsible for this altered response. Recent studies have shown that differences in maternal care can elicit a form of "epigenetic programming" that changes the expression of genes, such as for glucocorticoid receptors, involved in the regulation of the HPA response (47) . This can result in an alteration in the amount of HPA negative feedback regulation, causing altered corticosterone responses. A similar alteration in the number, affinity, or efficacy of central glucocorticoid receptors may underlie our results, but the published data concerning the effect of neonatal immune challenges on glucocorticoid receptors are inconclusive (48, 49) . It has also been reported that neonatal events can change the level of key mediators of the HPA response, such as corticotrophin releasing hormone (CRH) in the paraventricular nucleus of the hypothalamus (49, 50) . Increased CRH drive in animals treated neonatally with LPS or altered downstream events in HPA activation (i.e., pituitary and adrenal sensitivity) are possible mechanisms underlying the enhanced HPA responses seen in this study. The exact contribution that CRH levels, GR feedback sensitivity or other alterations in the HPA axis has on the attenuation of the innate immune response seen after neonatal LPS challenge will need to be determined in future studies.
Recent observations (51, 52) concerning the influence of maternal care on subsequent stress responses raise the possibility that subtle differences in maternal care between the LPS and saline injected pups may be the cause of our altered HPA/febrile responses. Currently, there is no published literature on long-term alterations caused by changes in maternal care toward pups that received LPS (i.e., sick pups) vs. those that received saline alone (controls). However, we have made efforts to minimize differences in maternal care by ensuring that each litter contains the same number of both LPS and saline treated pups and that all pups are handled identically. In addition, it has been suggested that by the second week of life (P14) the influence of stressful neonatal events is less evident than in much younger pups (53) . It has also been thought that changes elicited during the neonatal period cannot solely be mediated by changes in maternal care (54) , thus the altered innate immune response seen here is likely mediated by events directly attributable to the neonatal immune challenge.
In summary, we have provided evidence that a single neonatal immune challenge can program the innate immune response to an adult LPS challenge. Here we have shown that this occurs through a mechanism involving a corticosterone-mediated suppression of cytokine synthesis, which can reduce the CNS-mediated febrile responses to an adult LPS challenge. The repercussions of this neonatal programming have yet to be elucidated. However, given the importance of febrile temperatures to an animal's ability to survive a potentially lethal infection (3, 4) , it is likely that alterations in this response could influence an individual's ability to combat infectious disease later in life. Certainly, programming of the innate immune system by neonatal immune challenge may provide a basis for individual differences in the pathogenesis of infectious disease. P>0.05, n=6) . However, when treated with LPS as adults, animals that had received LPS neonatally displayed significantly higher corticosterone responses when compared with animals that had received saline neonatally (t=60, **P<0.01, n=6). By 120 min after LPS challenge, the corticosterone levels in the 2 neonatal treatment groups were no longer significantly different (t=120, P>0.05, n=6). 
